Astellas pharmaceuticals news

Astellas said it will close its OSI Pharmaceuticals LLC and Perseid Therapeutics LLC units and scale back its Astellas Research Institute of America LLC unit to focus on CNS therapies as part of an R&D restructuring. The company expects to reduce headcount by about 200 in the restructuring. An Astellas spokesperson said the pharma has 3,000 employees in the U.S., but declined to specify whether that includes the 200 positions being eliminated. Astellas said the closures of OSI and Perseid will come during its FY13, which ends March 31, 2014, and that projects from the facilities will be moved elsewhere. ...